Merck’s Clark: 2009 is a Year of Fundamental Change
In 2009, Merck is implementing a new business model that fundamentally transforms the company and is crucial to its future, CEO Richard Clark told analysts at a Goldman Sachs health care conference Jan. 7
You may also be interested in...
Speaking at a Goldman Sachs investor conference, CEO Clark discusses Merck’s plans in biotech.
Facing lower sales of Vytorin, Singulair and Gardasil, on top of recent pipeline disappointments, Merck implements a new restructuring initiative.
Merck expects to reduce its marketing spend by about 15 to 20 percent per product, Global Pharmaceuticals President Adam Schechter told the Pharmaceutical Strategic Alliances conference in New York on September 25